https://www.zonebourse.com/cours/action/DAIICHI-SANKYO-CO-LTD-6498062/actualite/Demande-de-modification-de-type-II-du-trastuzumab-deruxtecan-validee-par-l-Ema-pour-les-patientes-a-37430734/?utm_source=telegram&utm_medium=social&utm_campaign=share